Vivo Capital
Vivo is a global investment firm focused on healthcare with approximately $5.8 billion in AUM
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Vivo Capital Information
Geographic Data
Address: 575 High St Ste 201
City: Palo Alto
State: CA
Zip: 94301
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
2,761,045Website Global Rank
6,244Website Monthly Traffic
Twitter Followers
Description
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists, entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Contact Phone:
+16506880818
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2018 | TOT BIOPHARM | Series B | 102M |
| 12/2020 | Provivi | Series C | 0 |
| 5/2014 | Coherus Biosciences | Series C | 54.7M |
| 11/2007 | Carbylan Therapeutics | Series B | 20M |
| 4/2011 | Eiger BioPharmaceuticals | Series A | 14.5M |
| 6/2010 | Vicept Therapeutics | Series A | 16M |
| 3/2004 | Aspreva Pharmaceuticals Corp | Series A | 57M |
| 12/2014 | Ascendis Pharma | Series D | 60M |
| 7/2019 | Revolution Medicines | Series C | 100M |
| 7/2018 | Sinovac Biotech | Post-IPO Equity | 86.7M |
| 1/2019 | Innocare | Private Equity Round | 0 |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 2/2021 | Innocare | Post-IPO Equity | - |
| 9/2018 | AirXpanders | Post-IPO Equity | 15M |
| 3/2023 | EpiBiologics | Series A | 0 |
| 9/2014 | AirXpanders | Series E | 1M |
| 4/2012 | AirXpanders | Series D | 11M |
| 1/2012 | AirXpanders | Series D | 10.3M |
| 1/2021 | Serán Bioscience | Venture Round | - |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
| 1/2013 | Carbylan Therapeutics | Venture Round | 6M |
| 9/2022 | Allakos | Post-IPO Equity | 0 |
| 8/2011 | Ceptaris Therapeutics | Series D | 14.4M |
| 6/2012 | Ceptaris Therapeutics | Series D | 10M |
| 8/2020 | ESSA Pharma | Post-IPO Equity | 0 |
| 12/2009 | Revance Therapeutics | Series D | 0 |
| 4/2004 | Revance Therapeutics | Series B | 13M |
| 4/2018 | Poseida Therapeutics | Series B | 0 |
| 1/2021 | Visen Pharmaceuticals | Series B | 0 |
| 8/2021 | Neurogastrx | Series B | 60M |
| 1/2000 | Med-eCommerce.com | Venture Round | 2M |
| 11/2002 | Copernicus Therapeutics | Venture Round | 2M |
| 10/2014 | Aclaris Therapeutics | Series B | 21M |
| 7/2015 | Gengmei | Series B | - |
| 9/2015 | Aclaris Therapeutics | Series C | 40M |
| 2/2021 | ASLAN Pharmaceuticals | Post-IPO Equity | 18M |
| 5/2021 | Scientia Vascular | Private Equity Round | 50M |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 1/2005 | NextWave Pharmaceuticals | Series A | 10M |
| 12/2022 | Ronovo Surgical | Series B | - |
| 2/2003 | AgraQuest | Venture Round | 9.4M |
| 11/2011 | Medley Health | Series A | 20M |
| 8/2017 | Amyris | Post-IPO Equity | 50M |
| 2/2018 | Innocare | Private Equity Round | 55M |
| 6/2018 | Cerebral Therapeutics | Series A | 3M |
| 7/2022 | Tebra | Series B | 0 |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 11/2015 | Crinetics Pharmaceuticals | Series A | 40M |
| 1/2015 | Synapse Biomedical | Venture Round | - |
| 9/2008 | Sagent Pharmaceuticals | Series A | 30M |
| 9/2007 | Sagent Pharmaceuticals | Series A | 53M |
| 12/2021 | Avistone Pharmaceuticals | Private Equity Round | 0 |
| 11/2017 | OMNI | Series C | - |
| 11/2019 | Genetron Health | Series D | 71M |
| 8/2008 | InteKrin | Series C | 0 |
| 6/2017 | Platelet BioGenesis | Series A | 0 |
| 5/2021 | Larimar Therapeutics | Post-IPO Equity | 0 |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 7/2020 | Bolt Biotherapeutics | Series C | 93.5M |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 1/2007 | InteKrin | Series B | 0 |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 4/2022 | Visirna Therapeutics | Seed Round | 0 |
| 6/2020 | Mereo Biopharma | Post-IPO Equity | 0 |
| 7/2016 | Tricida | Series C | 0 |
| 3/2023 | Unicycive Therapeutics | Post-IPO Equity | 0 |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 3/2020 | Rongchang Pharmaceutical | Series A | - |
| 6/2013 | AirXpanders | Series E | 9M |
| 1/2021 | Terns Pharmaceuticals | Series C | 87M |
| 6/2012 | SentreHEART | Series C | 26M |
| 9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
| 4/2021 | Sera Prognostics | Series E | 0 |
| 12/2016 | Impel NeuroPharma | Series C | 36M |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 11/2015 | Celladon | Post-IPO Equity | 39.5M |
| 2/2020 | ALX Oncology | Series C | 105M |
| 11/2007 | Ceptaris Therapeutics | Series C | 14.5M |
| 10/2018 | Terns Pharmaceuticals | Series B | 80M |
| 1/2020 | Cerebral Therapeutics | Series B | 35M |
| 9/2019 | Passage Bio | Series B | 110M |
| 3/2007 | Transcept Pharmaceuticals | Series D | 40M |
| 4/2014 | Nora Therapeutics | Series B | 18M |
| 1/2018 | Aligos Therapeutics | Series A | 100M |
| 6/2016 | Verona Pharma | Post-IPO Equity | 65.6M |
| 3/2021 | BlossomHill Therapeutics | Series A | 71M |
| 4/2015 | Nabriva Therapeutics | Series B | 0 |
| 11/2017 | Tricida | Series D | 0 |
| 9/2021 | Attralus | Series B | 116M |
| 12/2018 | Impel NeuroPharma | Series D | 67.5M |
| 2/2009 | Eiger BioPharmaceuticals | Series A | 8.3M |
| 12/2004 | Prestwick Pharmaceuticals | Series B | 37M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 5/2021 | Aerobiotix | Venture Round | 0 |
| 1/2010 | Neomend | Series D | 30M |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 6/2009 | Sagent | Series A | 30M |
| 10/2003 | Cotherix | Series C | 55M |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 7/2019 | IGM Biosciences | Series C | 102M |
| 10/2017 | Harmony Biosciences | Venture Round | 0 |
| 4/2021 | Ronovo Surgical | Series A | - |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 2/2007 | NextWave Pharmaceuticals | Series B | 40M |
| 8/2007 | Prestwick Pharmaceuticals | Venture Round | 20M |
| 10/2020 | Gracell Biotechnologies | Series C | 0 |
| 6/2003 | Prestwick Pharmaceuticals | Series A | 15M |
| 3/2022 | Ocelot Bio | Series A | 0 |
| 2/2017 | Bristol Myers Squibb | Post-IPO Equity | 80M |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 5/2021 | Rgenta Therapeutics | Seed Round | 18M |
| 8/2020 | PatientPop | Series C | 50M |
| 11/2015 | VYNE Therapeutics | Series B | 45M |
| 10/2019 | dMed | Series B | 50M |
| 3/2020 | Remegen | Private Equity Round | 0 |
| 1/2021 | IO Biotech | Series B | 0 |
| 10/2020 | Neocis | Series D | 72M |
| 10/2022 | Neocis | Series D | 0 |
| 7/2020 | Preventice Solutions | Series B | 0 |
| 3/2019 | MacuLogix | Series D | 0 |
| 6/2018 | Metacrine | Series C | 65M |
| 3/2019 | Cerebral Therapeutics | Series A | 7.8M |
| 3/2021 | Ossium Health | Series B | 63M |
| 9/2016 | ReadCoor | Series A | 23M |
| 1/2011 | NextWave Pharmaceuticals | Series C | 45M |
| 7/2008 | TRIA Beauty | Series E | 30M |
| 6/2011 | Revance Therapeutics | Series D | 45M |
| 2/2011 | TRIA Beauty | Venture Round | 26.3M |
| 10/2012 | TRIA Beauty | Venture Round | 7.5M |
| 7/2013 | TRIA Beauty | Private Equity Round | 0 |
| 10/2002 | Oculex Pharmaceuticals | Series B | 50M |
| 9/2018 | Immune-Onc Therapeutics | Series B | 33M |
| 10/2006 | Prestwick Pharmaceuticals | Series C | 60M |
| 9/2015 | Akari Therapeutics | Post-IPO Equity | 0 |
| 11/2018 | Visen Pharmaceuticals | Series A | 0 |
| 11/2017 | Medeor Therapeutics | Series B | 0 |
| 10/2004 | MacroGenics | Series B | 30.5M |
| 11/2022 | Rgenta Therapeutics | Series A | 0 |
| 7/2020 | Citrine Medicine | Series A | 0 |
| 9/2008 | APT Pharmaceuticals | Series B | 32M |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 6/2022 | DBV Technologies | Post-IPO Equity | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 5/2021 | Esco Lifesciences | Series A | 0 |
| 10/2012 | Aclaris Therapeutics | Series A | 21M |
| 8/2017 | Apellis Pharmaceuticals | Series E | 0 |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
| 9/2016 | SentreHEART | Series D | 35M |
| 6/2021 | RayzeBio | Series C | 108M |
| 5/2017 | Aadi | Series A | 23M |
| 6/2017 | Zai Lab | Series C | 30M |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 9/2016 | Fortis Therapeutics | Series A | 18M |
| 3/2021 | Fortis Therapeutics | Series A | 0 |
| 4/2020 | Legend Biotech | Series A | 0 |
| 11/2013 | Ocera Therapeutics | Post-IPO Equity | 0 |
| 12/2022 | Pulmocide | Series C | 0 |
| 11/2022 | Bonum | Series A | 93M |
| 5/2004 | CAPNIA | Series B | 12M |
| 9/2021 | INBRACE | Series D | 0 |
| 2/2019 | Bolt | Series B | 54M |
| 5/2015 | REGENXBIO | Series D | 0 |
| 11/2004 | ViOptix | Series C | 0 |
| 10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
| 12/2007 | Revance Therapeutics | Series C | 0 |
| 3/2017 | Angiotech Pharmaceuticals | Venture Round | - |
| 3/2021 | Immune-Onc Therapeutics | Series B | 0 |
| 10/2020 | Olema Oncology | Series C | 85M |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 4/2016 | Kala Pharmaceuticals | Series C | 68M |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 7/2020 | Tranquis Therapeutics | Series A | 30M |
| 10/2019 | INBRACE | Series C | 45M |
| 3/2021 | OMNI | Series D | - |
| 9/2017 | Kadmon | Post-IPO Equity | 80.4M |
| 10/2021 | HistoWiz | Series A | 32.3M |
| 6/2022 | Cerebral Therapeutics | Series C | 40M |
| 1/2021 | Kira Pharmaceuticals | Series B | 53.5M |
| 3/2021 | Satsuma Pharmaceuticals | Post-IPO Equity | 0 |
| 11/2012 | MEI Pharma | Post-IPO Equity | 27.5M |
| 8/2022 | Klavi | Series A | 15M |
| 12/2020 | dMed | Series C | 100M |
| 10/2007 | APT Pharmaceuticals | Series A | 22M |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 7/2022 | Tebra | Series B | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 0 |
| 6/2022 | DBV Technologies | Post-IPO Equity | 0 |
| 4/2022 | Visirna Therapeutics | Seed Round | 0 |
| 3/2022 | Ocelot Bio | Series A | 0 |
| 12/2021 | Avistone Pharmaceuticals | Private Equity Round | 0 |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 10/2021 | HistoWiz | Series A | 0 |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
